I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan as the Company’s new Chief Executive Officer and a member of the board of directors effective June 22, 2023. This appointment serves as a significant step towards further realizing I-Mab’s mission of delivering transformative therapies to patients worldwide.
Raj Kannan has over 30 years of industry experience in creating and developing global specialty medicine franchises as a biotech CEO. Mr. Kannan has successfully led blockbuster product launches across several therapeutic areas including oncology both in the U.S. and globally. More recently, as the Chief Executive Officer of Aerie Pharmaceuticals, and before that of Chiasma Pharmaceuticals, he delivered significant value to shareholders exiting both companies successfully while increasing the potential reach of approved and candidate medicines. Mr. Kannan’s bio can be found here.
“I am very pleased to welcome Mr. Raj Kannan on board. Raj joins the Company at a critical juncture to strengthen its strategic position as a U.S.-based global company. Raj is a distinguished leader with the global experience and vision to drive sustainable growth and realize the full potential of our differentiated oncology portfolio as we move into our next phase of growth and innovation,” said Dr. Jingwu Zang, Founder and Chairman of I-Mab. “I would also like to thank Dr. Andrew Zhu, who had served as acting Chief Executive Officer of the Company since September 2022. Andrew will continue to lead the Company’s R&D as President of I-Mab and serve as a member of the board of directors.”
“It is an exciting time to be joining I-Mab with the Company’s advanced and differentiated clinical assets generating promising clinical data,” said Mr. Kannan. “I look forward to working with Dr. Zang and the talented team at I-Mab to further advance the robust pipeline to deliver on the full potential of the portfolio globally.”
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.
